FDA Tweaks PDUFA for Biosimilar User Fees
By Mari Serebrov
Tuesday, May 10, 2011
WASHINGTON The FDA sees a $150,000 annual biosimilar product development fee as the solution to a unique challenge posed by the new 351(k) approval path.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.